# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Natsume Sōseki (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET023-SYN
- Date: 2026-06-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Haruka Lindqvist-Mori, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review: biopsy results, resistance testing, and eradication therapy. **S**

## History of present illness

Mr. Natsume returns two weeks after his endoscopy. The epigastric pain stopped within four days of starting vonoprazan, and he now sleeps through the night. His stools are dark and formed on iron, with no sticky, tarry stools; he has not vomited or felt faint. He takes the iron every other morning without stomach upset. He has taken no NSAIDs. He is writing his serial again each morning and eats at more regular hours. **S**

| Element | Detail |
|---|---|
| Pain | Gone within four days of vonoprazan |
| Stools | Dark and formed on iron; no tarry stools |
| Medicines | Vonoprazan 20 mg each morning; ferrous sulfate every other morning; no NSAIDs |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy a little better; no fever |
| Gastrointestinal | Negative | No epigastric pain, vomiting, or tarry stools; dark formed stools on iron |
| Cardiovascular | Negative | No lightheadedness |
| Integumentary | Negative | No rash |

4 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, one or two tablets by mouth every six hours as needed for headache or pain, no more than 3 g a day (in place of ibuprofen) **S**
- Vonoprazan 20 mg oral tablet, one tablet by mouth each morning for eight weeks for gastric ulcer healing **S**
- Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other day **S**
- Vonoprazan 20 mg oral tablet, one extra tablet by mouth each evening for 14 days during eradication therapy (20 mg twice daily with the morning dose) **S**
- Amoxicillin 500 mg oral capsule, two capsules (1 g) by mouth three times daily for 14 days **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/76 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 52.2 kg; BMI 20.6 kg/m². All vital signs are synthetic.

Hemoglobin: 11.8 g/dL (low). All results are synthetic.

## Change since baseline

- Hemoglobin: 11.2 g/dL (low) at baseline, 11.8 g/dL (low) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 52.2 kg; pulse 78, blood pressure 120/76 |
| Abdomen | Soft and non-tender |
| Conjunctivae | Slightly pale |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Gastric ulcer, healing** (K25.4). The six margin biopsies show a benign ulcer with no dysplasia or cancer. Symptoms have settled on vonoprazan. **S**
   - Continue vonoprazan 20 mg each morning to complete eight weeks.
   - Repeat endoscopy with biopsy of the scar at about ten weeks, because cancer cannot be fully excluded until a gastric ulcer has healed.
2. **Helicobacter pylori infection, clarithromycin-resistant** (B96.81). Histology confirms H. pylori, and PCR shows a 23S rRNA mutation conferring clarithromycin resistance, so clarithromycin-based triple therapy would probably fail. Bismuth quadruple therapy is not available for this use in Japan. Vonoprazan-amoxicillin dual therapy for 14 days is the best choice: it needs no clarithromycin, and amoxicillin resistance is rare. No penicillin allergy. **S**
   - Vonoprazan 20 mg twice daily (an extra evening dose) with amoxicillin 1 g three times daily for 14 days, from today.
   - Expect loose stools or a metallic taste; call for watery diarrhea, rash or blood.
   - Urea breath test at least four weeks after the antibiotics and two weeks after stopping vonoprazan.
3. **Chronic atrophic gastritis with intestinal metaplasia** (K29.40). The mapping biopsies show chronic active gastritis with moderate atrophy and focal intestinal metaplasia in the antrum (OLGA stage II, OLIM stage I) and no dysplasia. Eradication lowers but does not remove the risk of gastric cancer, so he needs endoscopic surveillance after eradication. **S**
   - Upper endoscopy yearly after eradication.
   - No smoking; little alcohol; less salt and pickled food.
4. **Iron-deficiency anemia** (D50.0). Hemoglobin 11.8 g/dL, up 0.8 g/dL in two weeks: responding. **S**
   - Continue ferrous sulfate every other morning.
   - Blood count in about four weeks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Upper endoscopy with biopsy of the ulcer margin | At diagnosis; repeat for a gastric ulcer at 8 to 12 weeks to confirm healing and biopsy the scar | Completed today | Margin biopsies benign; no dysplasia or cancer; repeat endoscopy at about ten weeks |
| Laboratory | Helicobacter pylori test (rapid urease test and histology) with clarithromycin-resistance testing | At diagnosis | Completed today | Histology positive; clarithromycin-resistance mutation on PCR |
| Medication safety | Eradication therapy: adherence and side effects | At the start and during the course | Completed today | Vonoprazan-amoxicillin dual therapy for 14 days started today; adherence and side effects explained |
| Laboratory | Test of eradication (13C urea breath test) | At least four weeks after antibiotics and two weeks after acid suppression | Due | About seven weeks after the course ends |
| Medication safety | Acid suppression for ulcer healing (vonoprazan) | Daily for eight weeks for a gastric ulcer | Completed today | Taking vonoprazan each morning; pain gone |
| Medication safety | NSAID avoidance | Every visit | Completed today | None taken |
| Self-management | Bleeding warning signs and when to call 119 | Every visit | Completed today | No tarry stools or vomiting; dark stools on iron explained |
| Self-management | Alcohol, smoking and meals | Every visit | Completed today | Meals more regular; no smoking; less salt advised |
| Laboratory | Blood count on oral iron | About four weeks after starting oral iron, then every three months for a year (CMID) | Completed today | Hemoglobin 11.8 g/dL two weeks after starting iron, up 0.8 g/dL; next at about four weeks |
| Laboratory | Gastric cancer surveillance: atrophy and intestinal metaplasia staging | At diagnosis, then endoscopy yearly after eradication when atrophy or intestinal metaplasia is present | Completed today | OLGA stage II, OLIM stage I; open-type atrophy; no dysplasia: yearly surveillance |

## Goal progress

- Endoscopy within three days of the first visit, with cancer excluded by biopsy. Outcome by 2026-06-04: Endoscopy three days after the first visit; margin biopsies benign at two weeks. **S**
- No further bleeding and no emergency admission through the episode. In progress; target 2026-08-03. **S**
- Helicobacter pylori eradicated, confirmed by urea breath test. In progress; target 2026-08-03. **S**
- Gastric ulcer healed at repeat endoscopy. In progress; target 2026-08-03. **S**
- Hemoglobin normal and ferritin above 50 ng/mL. In progress; target 2026-08-03. **S**

## Medication changes

- Started: Vonoprazan 20 mg oral tablet, one extra tablet by mouth each evening for 14 days during eradication therapy (20 mg twice daily with the morning dose) **S**
- Started: Amoxicillin 500 mg oral capsule, two capsules (1 g) by mouth three times daily for 14 days **S**

## Guideline basis

- ACG Clinical Guideline: Treatment of Helicobacter pylori Infection (2024), American College of Gastroenterology (Am J Gastroenterol 2024;119(9):1730-1753)
- Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report (2022), European Helicobacter and Microbiota Study Group (Gut 2022;71(9):1724-1762)
- Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition (2016 (published 2019)), Japanese Society for Helicobacter Research (Helicobacter 2019;24(4):e12597)
- Evidence-based clinical practice guidelines for peptic ulcer disease 2026 (2026), Japanese Society of Gastroenterology (J Gastroenterol 2026;61(10):1361-1381)
- ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding (2021), American College of Gastroenterology (Am J Gastroenterol 2021;116(5):899-917)
- CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026), Aether Forge

## Follow-up

- Blood count in about four weeks. Eleven-week review in early August with the urea breath test, repeat endoscopy, blood count and ferritin. Call 119 for black, tarry stools, vomiting blood or fainting. **S**
- Next scheduled visit 2026-06-16: periodic adult preventive visit. **S**
